Opiant Pharmaceuticals (OPNT) Posts Wider Q1 Loss

May 10, 2022 5:01 PM UTC

Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q1 EPS of ($2.43), $1.52 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $5.9 million.

For earnings history and earnings-related data on Opiant Pharmaceuticals (OPNT) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings